Robertson G. 1972. ‘Thalidomide revisited’.J. Okla.
State Med. Assoc. 65 : 45.
Schreiber L, Hirssh HL. 1985. ‘Theories of liability
applied to overcome the unique ‘‘identification pro-
blem’’ in DES cases’.Med. Law 4 : 337.
Sherman M. 1986. ‘Thalidomide: a twenty-five year
perspective’.Food Drug Cosmetic Law J. 41 : 458–466.
Sindell v. Abbott Laboratories.1980. 26 Cal. 3d 588,
607 p. 2d 924, 163 Cal. Rptr. 132.
Szeinberg A. 1968. ‘Pharmacogenetics’.Israel J. Med.
Sci. 4 (3): 488.
The Progress & Freedom Foundation. 1996.Advancing
Medical Innovation: Health, Safety and the Role of
Government in the 21st Century.The Progress &
Freedom Foundation: Washington, DC.
Summers v. Tice.1948. 33 Cal. 2d 80, 199 P. 2d 1.
The Sunday Times. 1973.The Thalidomide Children
and the Law.Andre Deutsch: London.
US HHS. 1997. MIH will hold public Scientific work-
shop on thalidomide – potential benefits and risks.
9 August 1997, M2 Presswire.
Waterhouse R. 1995. ‘Thalidomide victims given £3.75
million bail-out’.The Independent, 4 May; 2.
Wiedemann HR. 1961. ‘Hinweis auf eine derzeitige
Haufung hypo-und aplasticher Fehlbildungen der
Gliedmassen’.Med. Welt. 37 : 1864.REFERENCES 617